ENLIGHTEN 2: A Phase III, Randomized, Blinded, Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis (CRS) in Adults (LYR-210-2021-005)
Principal Investigator
Study Number
STUDY02001497
Summary
Chronic rhinosinusitis is a condition where there is inflammation (swelling) in the nasal passage lasting for more than 12 weeks. The major symptoms include a blocked nose or congestion, facial pressure or pain, nasal discharge (mucus), and reduction or loss of smell. The LYR-210 System is comprised of a drug matrix packaged within a single-use applicator. The drug matrix contains 7500 µg of mometasone furoate (MF), embedded in bioabsorbable polymers. Mometasone furoate is a topical anti-inflammatory corticosteroid drug used as a nasal spray for CRS, allergic rhinitis, and nasal polyps (growth on the lining of the nose or sinuses) and as an inhaler for asthma. The drug matrix is small and flexible and is designed to fit within the nasal cavity. It is administered to the inside of the nose through the applicator
Phase
III
Contact
Available at the following location(s)
- Lebanon
View more details at ClinicalTrials.gov
Do you need help with some of the labels on this page?
Read our glossary of terms